Sulodexide and Alzheimer’s Disease: A Preliminary Prospective Study  

作　　者：Joaquín Lasierra-Cirujeda María José Aza Pascual-Salcedo María Mercedes Aza Pascual-Salcedo Joaquín Lasierra-Cirujeda;María José Aza Pascual-Salcedo;María Mercedes Aza Pascual-Salcedo(C. Medicine Hematology, Logrono, Spain;The Rioja and Pharmaceutical Act, Ministry of Health, The Rioja Regional Government, Logrono, Spain;Aragon Health Service, Zaragoza, Spain)

机构地区：[1]C. Medicine Hematology, Logrono, Spain [2]The Rioja and Pharmaceutical Act, Ministry of Health, The Rioja Regional Government, Logrono, Spain [3]Aragon Health Service, Zaragoza, Spain

出　　处：《World Journal of Cardiovascular Diseases》2016年第2期54-71,共18页心血管病（英文）

摘　　要：The purpose of this prospective study is to determine the relative incidence of Alzheimer’s disease in patients treated for at least three years, with sulodexide (n = 46, 76.48 ± 7.02 years old) or acenocoumarol (n = 47, 78.21 ± 6.66 years old) in order to prevent primary and secondary venous thromboembolism and atherothrombotic disease. In the sulodexide group, there was an apparent prevention of cognitive and behavioural impairment (relative incidence: 2.02) compared with acenocoumarol group (relative incidence: 4.86). The favourable results in sulodexide group may be related to their pharmacodynamic actions of inhibition of PAI-1, which may interfere with the pathogenesis of Alzheimer’s disease, and to the role of glutathione and PAI-1 in the β-amyloid system in the brain.The purpose of this prospective study is to determine the relative incidence of Alzheimer’s disease in patients treated for at least three years, with sulodexide (n = 46, 76.48 ± 7.02 years old) or acenocoumarol (n = 47, 78.21 ± 6.66 years old) in order to prevent primary and secondary venous thromboembolism and atherothrombotic disease. In the sulodexide group, there was an apparent prevention of cognitive and behavioural impairment (relative incidence: 2.02) compared with acenocoumarol group (relative incidence: 4.86). The favourable results in sulodexide group may be related to their pharmacodynamic actions of inhibition of PAI-1, which may interfere with the pathogenesis of Alzheimer’s disease, and to the role of glutathione and PAI-1 in the β-amyloid system in the brain.

关 键 词：SULODEXIDE Alzheimer’s Disease GLUTATHIONE t-PA PAI-1 PLASMINOGEN PLASMIN 

分 类 号：R74[医药卫生—神经病学与精神病学]